• The main objective of the NABARSI project is to develop a Proof-of-Concept (PoC) for the discovery of new chemical entities (NCEs) as antibacterial drugs, and to exploit the results in conjunction with industry.

  • Novel computational and screening technologies, synthetic methodology and advanced mechanistic studies will be combined with state-of-the-art drug discovery approaches in order to provide selective NCEs with high antibacterial efficacy and low resistance potential.

  • Specifically, NABARSI will identify inhibitors of aminoacyl-tRNA synthetases (aaRS). The PoC strategy and results will be evaluated using in vitro studies of multi-drug resistant (MDR) pathogenic bacteria belonging to the ESKAPE group of bacterial pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) and Escherichia coli. Antibacterial aaRS will also be initially validated in an animal model of infection.

  • Co-development of the antimicrobial molecules will be sought through collaboration and/or licensing with medium and large pharmaceutical and biotechnology companies, to the benefit of both parties. OMNIA's experience and network will be key to successfully achieving these aims. The project will also boost innovation within SMEs, strengthening the companies within the consortium and increasing their visibility worldwide.

  • Validation of this protein family as a target for antibacterials has been provided by the already marketed drug mupirocin and by other compounds in clinical development. Ultimately, we will develop NCE inhibitors that are active against multiple unexploited aaRS enzymes; this ‘multi-target’ approach will restrict the emergence of resistance to these new antimicrobial compounds.